Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 1943-1948

  Fan, Zhen ^a,c   Shang, Barbara Y ^b   Lu, Yang ^a   Chou, Jia Ling ^b   Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY MAB 225; PROTEIN P27; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DNA CONTENT; ENZYME INACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; KINETICS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030693984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ozanne, B., Richards, C. S., Hendler, F., Burns, D., and Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinoma. J. Pathol., 149: 9-14, 1986.
2. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of messenger RNAs for transformed growth factors a and β and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707-712, 1987.
3. Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., MacLeod, C. L., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.
4. Kawamoto, T., Sato, J. D., Le, A., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA., 80: 1337-1341, 1983.
5. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
6. Fan, Z., Masui, H., Altas, I., and Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragment of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 55: 4322-4328, 1993.
7. Fan, Z., Lu, Y., Wu, X., and Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem., 269: 27595-27602, 1994.
8. Ennis, B. W., Valverius, E. M., Lippman, M. E., Bellot, F., Kris, R., Schlessinger, J., Masui, H., Goldenberg, A., Mendelsohn, J., and Dickson, R. B. Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and non-malignant human mammary epithelial cells. Mol. Endocrinol., 3: 1830-1838, 1989.
9. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1404, 1996.
10. Karnes, W. E., Jr., Walsh, J. H., Wu, S. V., Kim, R. S., Martin, M. G., Wong, H. C., Mendelsohn, J., Park, J-G., and Cuttitta, F. Autonomous proliferation of colon cancer cells that coexpress transforming growth factor α and its receptor. Gastroenterology, 102: 474-485, 1992.
11. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C., and Kozlowski, J. M. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res., 51: 2780-2785, 1991.
12. 1 arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.
13. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W., and Mendelsohn, J. Anti-tumor effects in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
14. Prewett, M., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., Scher, H. I., and Goldstein, N. I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunotherapy, 19: 419-427, 1996.
15. Divgi, C. R., Welt, C., Kris, M., Real, F. X., Yeh, S. D. J., Gralla, R., Merchant, B., Schweighart, S., Unger, M., Larson, S. M., and Mendelsohn, J. Phase I and imaging trial of indium-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst., 83: 97-104, 1991.
16. Kawamoto, T., Mendelsohn, J., Le, A., Sato, G. H., Lazar, C. S., and Gill, G. N. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem., 259: 7761-7766, 1984.
17. Gill, N. G., and Lazar, C. S. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature (Lond.), 293: 305-307, 1981.
18. Barnes, D. W. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J. Cell Biol., 93: 1-4, 1982.
19. Fernandez-Pol, J., Klos, A. D., and Grant, G. A. Purification and biological properties of type β transforming growth factor from mouse transformed cells. Cancer Res., 46: 5153-5161, 1986.
20. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
21. Van de Vijver, M., Kumar, R., and Mendelsohn, J. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J. Biol. Chem., 266: 7503-7508, 1991.
22. Kip1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
23. 1 control in mammalian cells. J. Cell Sci. (Suppl.), 18: 69-73, 1994.
24. ip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes & Dev., 8: 9-22, 1994.
25. Kwok, T. T., Mok, C. H., and Menton-Brennan, L. Up-regulation of a mutate form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res., 54: 2834-2836, 1994.
26. 1 events. Cancer Res., 57: 1750-1757, 1997.